No abstract

Psoriasis is an immune-mediated chronic inflammatory disease. There are several intrinsic and extrinsic factors that can initiate the disease in predisposed individuals and its exacerbation, with vaccination against COVID-19 being a relevant factor. The objective of the present study is to review the exacerbation of psoriasis, in patients already diagnosed and in new cases, after vaccination against COVID-19, trying to establish a causal relationship on which vaccines are most related to decompensation of the condition, having based on the cases reported so far in the literature. Furthermore, it is intended to elucidate the main hypotheses for this phenomenon. The search for articles was carried out in the Pubmed/Medline, SciELO, Cochrane Library and LILACS databases, using the following descriptors: Psoriasis; Exacerbation; COVID-19; Vaccination; Psoriasis; Exacerbation; COVID-19; Vaccine. The search was restricted to articles published from 2019 to 2022, and studies relevant to the topic were selected. After analyzing the selected articles, several cases of psoriasis flare were seen after vaccination, in particular the Pfizer and Astrazeneca vaccines. Therefore, physicians and other healthcare professionals should be aware of the possibility of manifestation and exacerbation of psoriasis after the COVID-19 vaccine, regardless of type and dose.

Psoriasis is a chronic, non-communicable disease for which there is no cure. It can involve skin, nails and joints and affected individuals are more susceptible to having comorbidities. The worldwide prevalence is approximately 2%, having a great impact on quality of life. Although the etiology is uncertain, the disease is believed to result from a complex interaction between genetics, environment and the immune system. The characteristic lesions of psoriasis are silvery-white scaly erythematous plaques, the most common subtype being psoriasis vulgaris. Because there is an environmental component involved, there are some triggers that can trigger the disease or exacerbate it, among them other infections, such as Covid-19, which was responsible for the pandemic that started in December 2019. The objective of this study is to make an analysis of documented cases of exacerbation of psoriasis by Covid-19. For this purpose, a search was carried out in Pubmed, LILACS, Science Direct, Scielo and Cochrane Library databases. Studies cite as a justification for this event, the emotional stress caused by social isolation, fear after diagnosis and the pathophysiology of Covid-19 itself, causing a greater inflammatory state in the affected individual.

The thyroid gland is the largest endocrine gland in the body. Among the functions of this gland, we can mention the secretion of the hormones thyroxine (T4) and triiodothyronine (T3), whose release occurs by the control of the thyroid stimulating hormone (TSH). Furthermore, it is involved in calcium metabolism, through the hormone calcitonin. Thyroid cancer is rare (about 1% of all neoplasms), however it is the most frequent among malignant endocrine neoplasms. Papillary thyroid carcinoma (PTC) accounts for more than 80% of thyroid carcinomas. In this study, bibliographic searches were carried out using the descriptors “papillary thyroid carcinoma” and “p53”; results elucidated the role of the p53 gene in the development of CPT. Due to the fundamental role of the p53 family in cellular changes, there is currently a representation of very attractive targets in the development of anticancer drugs. Thus, the new therapeutic targets indicate that, mainly, multikinase inhibitors (MKIs) may represent a potential therapeutic target.

Com uma forte predisposição genética, traços patogênicos autoimunes e com grande relação ao meio ambiente, a psoríase é uma doença crônica, não infecciosa, que acomete pessoas de todas as idades, sem predileção por sexo. O seu tratamento tem como principal objetivo controlar a diferenciação e a proliferação dos queratinócitos. Tendo isso em vista, o objetivo desta revisão narrativa é fazer uma análise do que já está documentado na literatura, envolvendo os efeitos da Cannabis sativa no tratamento da psoríase, com enfoque na sua efetividade. Para isso, foi feita uma busca ativa sobre o tema nas bases de dados Google Acadêmico, Pubmed e LILACS. Foi verificado que os canabinoides possuem um potencial terapêutico na psoríase, principalmente em relação à proliferação dos queratinócitos e na modulação da inflamação, porém a maioria dos estudos disponíveis são in vitro. É necessário a realização de mais estudos clínicos em humanos para melhor elucidação da eficácia e segurança dos canabinoides no tratamento da psoríase.